Disease Diagnosis TRIZ Cases

Detecting HPV stimulus molecules and endogenous antibodies in patient samples to evaluate immune system self-healing status.

A biomarker panel combines multiple proteins to detect early-stage pancreatic ductal adenocarcinoma.

Segmenting the macrocycle host from the affinity-tagged axle simplifies synthesis complexity while maintaining high xenon binding reliability.

Mass spectrometry quantifies LDL-triglycerides and specific biomarkers in blood to detect cardiovascular disease risk without invasive procedures.

Integrated substrate channels merge excitation and measurement units to reduce digital PCR equipment complexity.

A computing device processes encoded hCG-hg and progesterone levels to predict pregnancy outcomes.

Measuring GDF-15 levels in patient samples to predict disease severity and guide clinical risk stratification.

Soluble urokinase plasminogen activator receptor levels indicate low-grade inflammation status in biological fluids.

A multi-marker panel of serum biomarkers including TNFα, sTNFR1, sTNFR2, sFas, and IL-6 detects early renal function decline before proteinuria appears.

Mass spectrometry detects monoclonal free light chains in patient samples to identify minimal residual disease with high sensitivity.

Anti-DLL1 antibodies detect DLL1 protein to diagnose sepsis without blood cultures.

Antisense oligonucleotides target Shank3 pre-mRNA to boost protein expression, addressing genetic causes of Phelan-McDermid syndrome.

Measuring thioredoxin-1 concentrations in blood specimens differentiates ovarian cancer from pneumonia and inflammatory diseases.

Biomarker analysis identifies proinflammatory endophenotypes to predict patient response to Alzheimer's disease therapies.

Mass spectrometry measures vaginal microbes and immune responses simultaneously to resolve diagnostic accuracy versus method complexity.

ST2 biomarker levels provide reliable diagnosis for heart failure and pulmonary embolism despite misleading natriuretic peptide results in high BMI patients.

A multi-biomarker assay measures thirty-four proteins to evaluate lung cancer presence and treatment responsiveness.

Inhibiting VentX expression overcomes species-specific expansion limits, increasing CD34+ cell numbers for therapeutic use.

Segmenting LAG-3 expression profiling with SCARB1 genotyping improves diagnostic accuracy for atherosclerosis while managing assay complexity.

Modified H and proportion scores standardize PD-L1 expression quantitation in tumor tissue sections.

Segmenting endothelial antigens into distinct HLA and non-HLA panels resolves specificity conflicts, enabling accurate allograft rejection risk prediction.

Anti-pembrolizumab antibodies detect anti-drug antibodies by binding pembrolizumab, resolving assay complexity while ensuring monitoring accuracy.

A dynamic prediction model integrates proteomic data to identify biomarkers for cystic fibrosis patients.

Segmenting circulating from kidney-targeting antibodies resolves the trade-off between broad diagnostic scope and renal specificity, enabling early detection.

Calculating the GBP-1 to ESM-1 plasma ratio overcomes low predictive values of individual markers, enabling accurate rule-in and rule-out diagnosis.

Breath gas analysis detects volatile organic compounds to diagnose major depressive disorder without invasive blood sampling.

A lateral flow immunoassay device detects functional C1-esterase inhibitor using immobilized agents on a conjugate pad and membrane.

Measuring soluble ST2 levels predicts exercise therapy efficacy and reduces mortality risk in heart failure patients.

Detecting 14-3-3 autoantibodies resolves diagnosis delay by enabling early detection of arthritic conditions.

A portable assay device separates suspensions into filtrate and residue using a filter membrane and user actuated switch.

MALDI imaging mass spectrometry detects specific CRIP1 protein variants in breast cancer tissue samples for direct biomarker analysis.

A lectin recognizing the fucose α 1-2 galactose motif labels colorectal cancer stem cells for specific quantification.

Pro-Enkephalin biomarker levels enable sensitive detection of chronic kidney disease risk in diverse patient populations.

A multi-biomarker analysis method generates immune tolerance signatures from biological samples to track antigen-specific tolerance maintenance.

Detecting donor-specific MHC proteins on circulating exosomes resolves the trade-off between biopsy precision and patient invasiveness.

Analyzing TTR, DUOX2, and GPR179 expression resolves uterine leiomyosarcoma versus fibroid ambiguity for precise treatment selection.

Combining multiple metabolic markers improves prediction accuracy for kidney rejection risk assessment.

A biochemical assay measures MR-proANP levels in bodily fluids to determine atrial fibrillation onset time.

Homocysteic acid neutralizes reactive glutaraldehyde groups to enable accurate alpha-Gal epitope quantification via ELISA immunoassay.

Carbamylated biomarkers assess short-term cardiovascular complications by measuring modified protein levels in bodily fluids.

Targeted peptide antibodies detect glycogen phosphorylase isoenzyme BB earlier than troponin markers, enabling precise myocardial infarction diagnosis.

IHC analysis of hERG1 and Glut-1 expression resolves TNM staging variability by identifying stage I-II patients with poor prognosis.

Cells expressing expanded polyglutamine Huntingtin variants aggregate proteins from patient CSF to quantify disease severity.

Segmenting adrenomedullin into stable MR-proADM fragments resolves plasma instability issues for accurate diabetes risk assessment.

A severity score combining respiratory metrics and PSP/reg biomarkers enables rapid clinical assessment.

Multi-analyte biomarker panel stratifies prostate cancer risk to reduce unnecessary invasive biopsies and improve diagnostic accuracy.

Assess CD14+/DR- and CD4+ cell levels to classify patients, resolving suboptimal treatment choices by enabling tailored therapy selection.

Nanostructure-embedded chips isolate circulating trophoblasts from maternal blood to enable noninvasive biomarker analysis.